Product Name: TRKC (706-713) pY709+pY710
Product Number: PE-04AHW95
Size: 200 µg      Price:74.00
1 mg      $US148.00
5 mg      325.00
Peptide Name: TRKC (706-713) pY709+pY710

Product Use: Services as a blocking peptide for use with the TrkC-pY709+pY710 rabbit polyclonal antibody (Cat. No.: AB-PK840) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y709 and Y710 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: STD-pY-pY-RLF

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1397.33 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: TRKC - pY709+pY710 phosphosite-specific antibody (Cat. No.: AB-PK840)

Scientific Background: TrkC is a receptor protein-tyrosine kinase that is a member of the TK group of protein kinases in the Trk family. This kinase shows high variability in human tissue distribution with the highest levels detected in brain, liver, spinal cord and thymus. It is the high affinity catalytic receptor for the neurotrophin NT-3. TrkC is activated by phosphorylation at Y516. Phosphorylation of Y834 of TrkC induces interaction with PLCg1 and Shc1. TRKC mediates the multiple cellular effects of the NT-3 neurotrophic factor, which includes neuronal differentiation and survival. TrkC has been implicated in insulin signalling pathway through interactions with the MUSK protein receptor and the VEGF receptor. Mutations in the TrkC gene have been associated with medulloblastomas, secretory breast carcinomas and other cancers. TrkC has also been linked with the development of pediatric mesenchymal, colon, and large lung cell carcinomas (LLCC), and gastric and lung adenocarcinomas.